BACKGROUND: BCL6 gene rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma, a malignancy characterized by genetic heterogeneity and wide variability in clinical outcome. The prognostic significance of BCL6 rearrangement has not been evaluated in the context of rituximab therapy for diffuse large B-cell lymphoma. We analyzed the effect of the BCL6 rearrangement on survival in patients with diffuse large B-cell lymphoma treated with CHOP and CHOP plus rituximab (R-CHOP). DESIGN AND METHODS: BCL6 rearrangement status was analyzed by fluorescence in situ hybridization with break-apart probes in 164 patients with diffuse large B-cell lymphoma treated with CHOP (n=65) or R-CHOP (n=99). Cell-of-origin immunophenotype including BCL6 protein expression were determined by immunohistochemistry on a tissue microarray. RESULTS: BCL6 rearrangement was detected in 19.5% of cases. The presence of the gene rearrangement was associated with a non-germinal center B-cell immunophenotype (P=0.006), and showed no correlation with BCL6 protein expression. A trend toward inferior overall survival was observed in association with the BCL6 rearrangement among patients treated with R-CHOP (P=0.08), but not among patients treated with CHOP (P=0.64). However, BCL6 rearrangement also correlated with a high International Prognostic Index score (P=0.02), and did not demonstrate independent prognostic value by multivariate analysis. CONCLUSIONS: The introduction of rituximab may have altered the prognostic impact of BCL6 gene rearrangement in patients with diffuse large B-cell lymphoma. However, prospective analysis within large randomized clinical trials will be needed to clarify the prognostic significance of this biomarker in the rituximab era.
BACKGROUND:BCL6 gene rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma, a malignancy characterized by genetic heterogeneity and wide variability in clinical outcome. The prognostic significance of BCL6 rearrangement has not been evaluated in the context of rituximab therapy for diffuse large B-cell lymphoma. We analyzed the effect of the BCL6 rearrangement on survival in patients with diffuse large B-cell lymphoma treated with CHOP and CHOP plus rituximab (R-CHOP). DESIGN AND METHODS: BCL6 rearrangement status was analyzed by fluorescence in situ hybridization with break-apart probes in 164 patients with diffuse large B-cell lymphoma treated with CHOP (n=65) or R-CHOP (n=99). Cell-of-origin immunophenotype including BCL6 protein expression were determined by immunohistochemistry on a tissue microarray. RESULTS:BCL6 rearrangement was detected in 19.5% of cases. The presence of the gene rearrangement was associated with a non-germinal center B-cell immunophenotype (P=0.006), and showed no correlation with BCL6 protein expression. A trend toward inferior overall survival was observed in association with the BCL6 rearrangement among patients treated with R-CHOP (P=0.08), but not among patients treated with CHOP (P=0.64). However, BCL6 rearrangement also correlated with a high International Prognostic Index score (P=0.02), and did not demonstrate independent prognostic value by multivariate analysis. CONCLUSIONS: The introduction of rituximab may have altered the prognostic impact of BCL6 gene rearrangement in patients with diffuse large B-cell lymphoma. However, prospective analysis within large randomized clinical trials will be needed to clarify the prognostic significance of this biomarker in the rituximab era.
Authors: Sharon L Barrans; Sheila J M O'Connor; Paul A S Evans; Faith E Davies; Roger G Owen; Andrew P Haynes; Gareth J Morgan; Andrew S Jack Journal: Br J Haematol Date: 2002-05 Impact factor: 6.998
Authors: C Bastard; C Deweindt; J P Kerckaert; B Lenormand; A Rossi; F Pezzella; C Fruchart; C Duval; M Monconduit; H Tilly Journal: Blood Date: 1994-05-01 Impact factor: 22.113
Authors: U Vitolo; G Gaidano; B Botto; G Volpe; E Audisio; M Bertini; R Calvi; R Freilone; D Novero; L Orsucci; C Pastore; D Capello; G Parvis; C Sacco; V Zagonel; A Carbone; U Mazza; G Palestro; G Saglio; L Resegotti Journal: Ann Oncol Date: 1998-01 Impact factor: 32.976
Authors: Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier Journal: Blood Date: 2003-02-06 Impact factor: 22.113
Authors: K Offit; F Lo Coco; D C Louie; N Z Parsa; D Leung; C Portlock; B H Ye; F Lista; D A Filippa; A Rosenbaum Journal: N Engl J Med Date: 1994-07-14 Impact factor: 91.245
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: Rita Shaknovich; Huimin Geng; Nathalie A Johnson; Lucas Tsikitas; Leandro Cerchietti; John M Greally; Randy D Gascoyne; Olivier Elemento; Ari Melnick Journal: Blood Date: 2010-07-07 Impact factor: 22.113
Authors: Marie Jarosova; Eva Kriegova; Petra Schneiderova; Regina Fillerova; Vit Prochazka; Michaela Mikesova; Patrik Flodr; Karel Indrak; Tomas Papajik Journal: Pathol Oncol Res Date: 2015-08-30 Impact factor: 3.201
Authors: Christian Steidl; Sohrab P Shah; Bruce W Woolcock; Lixin Rui; Masahiro Kawahara; Pedro Farinha; Nathalie A Johnson; Yongjun Zhao; Adele Telenius; Susana Ben Neriah; Andrew McPherson; Barbara Meissner; Ujunwa C Okoye; Arjan Diepstra; Anke van den Berg; Mark Sun; Gillian Leung; Steven J Jones; Joseph M Connors; David G Huntsman; Kerry J Savage; Lisa M Rimsza; Douglas E Horsman; Louis M Staudt; Ulrich Steidl; Marco A Marra; Randy D Gascoyne Journal: Nature Date: 2011-03-02 Impact factor: 49.962
Authors: Qing Ye; Zijun Y Xu-Monette; Alexandar Tzankov; Lijuan Deng; Xiaoxiao Wang; Ganiraju C Manyam; Carlo Visco; Santiago Montes-Moreno; Li Zhang; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Ben M Parsons; Michael B Møller; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Shimin Hu; Ken H Young Journal: Oncotarget Date: 2016-01-19